AzTrials
AzTrials

Healthy AdultsNCT07567261

Efficacy and Safety of Repetitive Transcranial Magnetic Stimulation and Expressive Writing for Post-Traumatic Stress

A study testing Repetitive Transcranial Magnetic Stimulation and Expressive writing in people with Healthy Adults, run by Servicio Canario de Salud at 2 sites in Spain.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to learn if a combined treatment using repetitive transcranial magnetic stimulation (rTMS) and expressive writing works to reduce symptoms of post-traumatic stress in adults. It will also study how safe this treatment is and whether the timing of rTMS changes how well it works. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Healthy Adults
What is being tested?
Repetitive Transcranial Magnetic Stimulation and Expressive writing
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
45 participants
Where
2 sitesSpain
Study dates
Jun 2026to Feb 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Be between 18 and 65 years of age.
  • Have experienced at least one traumatic or highly stressful event, regardless of how much time has passed since the event occurred.
  • Present a score ≥ 24 on the Revised Impact of Event Scale (IES-R).
  • Have post-traumatic stress symptoms that are not better explained by another clinical condition or mental disorder.

Who cannot join

  • History of epilepsy, seizures, or convulsions.
  • Presence of intracranial or cranial metal incompatible with rTMS.
  • History of severe traumatic brain injury.
  • Pregnancy or reasonable possibility of pregnancy.
  • Cochlear implants or internal pulse generators.
  • Use of medication that lowers the seizure threshold.
Show all 11Show fewer
  • Current suicidal ideation or behaviour, or recent suicidal ideation within the past month.
  • Other medical or psychiatric conditions that contraindicate the use of rTMS.
  • Any condition that prevents participation in any of the study interventions.
  • Currently receiving psychological and/or pharmacological treatment for PTSD, acute stress, or another disorder that could account for post-traumatic stress symptoms.
  • Failure to provide written informed consent.

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Lilisbeth Perestelo-Pérez, Doctor in Psychology contact

+34 922478267

lilisbeth.peresteloperez@sescs.es

Wenceslao Peñate-Castro, Doctor in Psychology contact

wpenate@ull.edu.es

Spain2 sites
  • Instituto Universitario de Neurociencias (IUNE) de la Universidad de La Laguna (ULL)

    San Cristóbal de La Laguna, Santa Cruz de Tenerife, 38200

    Wenceslao Peñate-Castro, Doctor in Psychology, +34 922 31 74 60, wpenate@ull.edu.es

  • Servicio de Evaluación del Servicio Canario de Salud

    Santa Cruz de Tenerife, Santa Cruz de Tenerife, 38109

    Lilisbeth Perestelo-Pérez, Doctor in Psychology, +34 922478267, lilisbeth.peresteloperez@sescs.es

Other trials in Spain

About this study

Official title: Efficacy and Safety of a Combined Intervention of Repetitive Transcranial Magnetic Stimulation and Expressive Writing According to Timing of Administration: A Parallel-Group Randomized Controlled Trial in Adults With Post-Traumatic Stress Symptoms

The goal of this clinical trial is to learn if a combined treatment using repetitive transcranial magnetic stimulation (rTMS) and expressive writing works to reduce symptoms of post-traumatic stress in adults. It will also study how safe this treatment is and whether the timing of rTMS changes how well it works.

The main questions it aims to answer are:

Read more
  • Does this combined treatment lower symptoms of post-traumatic stress?
  • Does it work better when rTMS is given before or after expressive writing?

Researchers will compare three groups to see which approach works best:

  • rTMS given before expressive writing
  • rTMS given after expressive writing
  • Sham stimulation (a look-alike procedure that does not provide real stimulation)

Participants will:

  • Take part in sessions that include expressive writing about emotional experiences
  • Receive either real rTMS or sham stimulation
  • Complete questionnaires about post-traumatic stress, anxiety, depression, and mood
  • Have their heart rate and skin responses measured during the sessions
  • Be assessed before the study, after the sessions, and one month later

This study includes adults aged 18 to 65 who have experienced at least one traumatic or highly stressful event and report symptoms of post-traumatic stress.

Read the detailed description

Objective: To evaluate the efficacy and safety of a combined intervention consisting of repetitive transcranial magnetic stimulation (rTMS) and emotional re-experiencing through expressive writing, as well as to analyze the influence of the timing of rTMS application on clinical outcomes in adults with post-traumatic stress symptomatology.

Design: A randomized controlled superiority trial with three parallel groups: (1) rTMS administered 10 minutes prior to emotional re-experiencing via expressive writing, (2) rTMS administered 10 minutes after emotional re-experiencing, and (3) sham stimulation with an equivalent temporal structure. Assessments will be conducted at baseline, post-intervention, and at one-month follow-up.

Study setting: University Institute of Neurosciences (IUNE), University of La Laguna (ULL), located in San Cristóbal de La Laguna, Santa Cruz de Tenerife, Canary Islands, Spain.

Participants: Community-dwelling adults aged 18 to 65 years, exposed to at least one traumatic or highly stressful event, presenting post-traumatic stress symptomatology defined by a score ≥ 24 on the Revised Impact of Event Scale (IES-R). A total sample size of 45 participants is anticipated, distributed across three groups of 15 participants each.

Measures: Post-traumatic stress symptomatology will be assessed using the IES-R; anxiety symptoms using the GAD-7; and depressive symptoms using the PHQ-9. Affect will be assessed with the PANAS. Physiological arousal will be recorded via heart rate and skin conductance using a polygraph. rTMS will be delivered using a Magstim Rapid2 stimulator with a figure-of-eight coil, guided by BrainSight neuronavigation. Emotional re-experiencing will be induced through expressive writing.

Outcomes: The primary outcome will be the change in post-traumatic stress symptomatology. Secondary outcomes will include safety, measured by the frequency and type of adverse events and serious adverse events; changes in anxiety and depressive symptomatology; and situational changes in affect and physiological arousal during expressive writing sessions.

Data analysis: Baseline characteristics of each group will be presented in a descriptive table. Continuous variables will be summarized using means and standard deviations, whereas categorical variables will be reported as absolute and relative frequencies. Between-group differences at baseline will be explored using analysis of variance (ANOVA) for continuous variables and chi-square tests of independence for categorical variables. Assumptions of normality and homogeneity of variances will be assessed beforehand. When these assumptions are violated, non-parametric alternatives will be used, including the Kruskal-Wallis test for continuous variables and Fisher's exact test for categorical variables.

Intervention effects will be analyzed using linear mixed-effects models and, as a complementary approach, repeated-measures ANOVA. Main effects of group (sequential 1, sequential 2, and sham) and time (baseline, post-intervention, and one-month follow-up), as well as the group × time interaction, will be examined for the primary outcome (post-traumatic stress symptomatology) and secondary outcomes (anxiety symptoms, depressive symptoms, and situational changes).

Analyses will be conducted under both an intention-to-treat (ITT) and per-protocol (PP) framework. The ITT population will include all randomized participants who have received at least one rTMS session, consistent with previous research (Philip et al., 2019). The PP population will include participants who completed the assigned treatment without substantial protocol deviations.

For ITT analyses, missing data will be handled using linear mixed-effects models estimated via maximum likelihood, allowing the use of all available data under the assumption that missingness is at random (MAR). If evidence suggests that missing data may depend on unobserved variables (not missing at random, NMAR), sensitivity analyses will be conducted using pattern-mixture models or selection models to assess the robustness of the findings.

Subgroup analyses are not planned. Results will be reported in tables with descriptive statistics by group and time point. Effect sizes (Cohen's d and partial eta squared) will be reported along with 95% confidence intervals. The statistical significance threshold will be set at α = .05, with Bonferroni correction applied when appropriate for multiple comparisons. All analyses will be performed using R statistical software (R Core Team, 2025).

Conditions
Healthy Adults
Being tested
Repetitive Transcranial Magnetic Stimulation, Expressive writing, Sham rTMS
Keywords
Post-traumatic stress, rTMS, randomized controlled trial, repetitive transcranial magnetic stimulation, transcranial magnetic stimulation, TMS

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Repetitive Transcranial Magnetic StimulationDevice

    Also called rTMS

    rTMS will be administered by an experienced technician using a figure-of-eight coil connected to a Magstim Rapid2 stimulator (Magstim, Whitland, Dyfed, United Kingdom). Target localization will be performed using stereotactic neuronavigation with the frameless BrainSight system (Rogue Research, Canada) and a Polaris infrared tracking system (Northern Digital, Canada).

    Before each session and for each participant, the motor hotspot and resting motor threshold (rMT) will be determined. The hotspot will be defined as the stimulation site over the left primary motor cortex that produces the strongest and most consistent motor-evoked potentials in the first dorsal interosseous muscle, recorded via electromyography using a Biopac MP-35 system.

    The resting motor threshold will be defined as the minimum stimulation intensity capable of eliciting at least five small-amplitude motor responses out of ten stimuli applied to the relaxed muscle. The rTMS intensity will be individually adjusted

  • Expressive writingBehavioural

    Emotional re-experiencing will be induced through expressive writing. Participants will write for 15 minutes once per week about the thoughts and emotions associated with their traumatic or highly stressful experiences throughout the treatment period (Pennebaker \& Chung, 2011).

  • Sham rTMSDevice

    Sham stimulation will be delivered using a placebo coil that reproduces the acoustic and procedural characteristics of rTMS without producing effective cortical stimulation.

Study groups in NCT07567261
Study groupRoleWhat they receive
rTMS applied 10 minutes after emotional re-experiencing through expressive writing (SG1)ExperimentalBoth experimental groups will receive the same excitatory repetitive transcranial magnetic stimulation (rTMS) protocol targeting the right dorsolateral prefrontal cortex (rDLPFC). The stimulation protocol will consist of: * Frequency: 10 Hz * Intensity: 80% of resting motor threshold * Train duration: 4 seconds * Inter-train interval: 11 seconds * 50 trains per session * Approximately 12 minutes per session * Total of 2,000 pulses per session Treatment will be administered five days per week over three weeks, for a total of 15 sessions and 30,000 pulses. Emotional re-experiencing will be induced through expressive writing. Participants will write for 15 minutes once per week about the thoughts and emotions associated with their traumatic or highly stressful experiences throughout the treatment period. In this group, expressive writing will take place 10 minutes before the rTMS session.
Receives: Device: Repetitive Transcranial Magnetic Stimulation; Behavioral: Expressive writing
rTMS applied 10 minutes before emotional re-experiencing through expressive writing (SG2)ExperimentalBoth experimental groups will receive the same excitatory repetitive transcranial magnetic stimulation (rTMS) protocol targeting the right dorsolateral prefrontal cortex (rDLPFC). The stimulation protocol will consist of: * Frequency: 10 Hz * Intensity: 80% of resting motor threshold * Train duration: 4 seconds * Inter-train interval: 11 seconds * 50 trains per session * Approximately 12 minutes per session * Total of 2,000 pulses per session Treatment will be administered five days per week over three weeks, for a total of 15 sessions and 30,000 pulses. Emotional re-experiencing will be induced through expressive writing. Participants will write for 15 minutes once per week about the thoughts and emotions associated with their traumatic or highly stressful experiences throughout the treatment period. In this group, expressive writing will take place 10 minutes after the rTMS session.
Receives: Device: Repetitive Transcranial Magnetic Stimulation; Behavioral: Expressive writing
Sham stimulation combined with expressive writing, divided equally to mirror the two active armsSham comparatorSham stimulation will be delivered using a placebo coil that reproduces the acoustic and procedural characteristics of rTMS without producing effective cortical stimulation. Emotional re-experiencing will be induced through expressive writing. Participants will write for 15 minutes once per week about the thoughts and emotions associated with their traumatic or highly stressful experiences throughout the treatment period. This group will be divided into two halves, each mirroring the timing conditions of each experimental study arm.
Receives: Behavioral: Expressive writing; Device: Sham rTMS

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Post-traumatic stress symptoms

    Post-traumatic stress symptomatology will be assessed using the Revised Impact of Event Scale (IES-R), a 22-item self-report instrument designed to measure subjective distress associated with traumatic or highly stressful events. The scale evaluates three core dimensions: intrusion, avoidance, and hyperarousal. In the present study, the IES-R will be used both to quantify the severity of post-traumatic stress symptoms and to establish eligibility criteria.

    Measured: Assessment at baseline, immediately after treatment and one month follow-up

Secondary outcomes (5)
  1. Adverse events

    Safety will be described by the number of participants who experience adverse events (AEs) and serious adverse events (SAEs), as well as by the total number of AEs and SAEs observed. An adverse event is defined as any undesirable experience associated with the use of a medical product in a participant. A serious adverse event, according to the U.S. Food and Drug Administration (FDA), refers to any undesirable experience associated with a medical treatment that results in death, is life-threatening, requires hospitalization, leads to disability or permanent damage, necessitates intervention to prevent further harm, or results in any other significant medical consequence.

    Measured: Through study completion, an average of 2 months

  2. Anxiety

    Anxiety symptomatology will be assessed using the Generalized Anxiety Disorder-7 questionnaire (GAD-7). The GAD-7 is a brief 7-item self-report scale designed to evaluate the severity of generalized anxiety symptoms.

    Measured: Assessment at baseline, immediately after treatment and one month follow-up

  3. Depression

    Depressive symptomatology will be assessed using the Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a 9-item self-report measure designed to evaluate the severity of depressive symptoms.

    Measured: Assessment at baseline, immediately after treatment and one month follow-up

  4. Positive and negative affect

    Affect will be assessed using the Positive and Negative Affect Schedule (PANAS). The PANAS is a 20-item self-report scale composed of two 10-item subscales that measure positive affect and negative affect, respectively.

    Measured: Assessment immediately after every expressive writing session

  5. Physiological arousal

    Physiological arousal will be indexed by heart rate and skin conductance, which will be recorded using a polygraph.

    Measured: From start to end of every expressive writing session

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 May 2026
  2. Study startJun 2026 (estimated)
  3. Primary completionJan 2027 (estimated)
  4. Study completionFeb 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
45 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07567261
Sponsor's protocol ID
PI/FIISC/EMT-TEPT-2026
Status last verified
Apr 2026
First submitted
21 Apr 2026
Last updated
5 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified participant data, together with the statistical procedures used for analysis, will be made available as supplementary material in the final open-access publication of the study. The templates of all self-report measures used in the assessment will also be included. Participants will be informed of this procedure in the participant information sheet and will provide corresponding informed consent.

Questions about this trial

What is this clinical trial studying?

A study testing Repetitive Transcranial Magnetic Stimulation and Expressive writing in people with Healthy Adults, run by Servicio Canario de Salud at 2 sites in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 5 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Lilisbeth Perestelo-Pérez, Doctor in Psychology (+34 922478267, lilisbeth.peresteloperez@sescs.es), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Post-traumatic stress symptoms (time frame: Assessment at baseline, immediately after treatment and one month follow-up). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in